April 13 (Reuters) – Biotech startup Vaccitech, which owns the technology behind the COVID-19 vaccine developed by AstraZeneca Plc jointly with the Oxford University, said on Monday it was aiming for a valuation of up to $613 million in its U.S. initial public offering.
Reporting by Niket Nishant in Bengaluru
